Table 2. Changes in migraine days per month after preventive drug treatment for chronic migraine compared to placebo (original data).
| Active ingredient, dose, publication | Trial acronym | Phase | T, months | Placebo, N | Active, N | MD [95% CI] |
|---|---|---|---|---|---|---|
| Atogepant, 60 mg/day | PROGRESS | 3 | 3 | 246 | 256 | −1.8 [−2.9; −0.8] |
| Pozo-Rosich et al., 2023 (e13) | ||||||
| Eptinezumab, 100 mg/quarter | -/- | 2b | 3 | 116 | 118 | −2.1 [−3.8; −0.4] |
| Dodick et al., 2019 (e38) | ||||||
| Lipton et al., 2020 (e39) | PROMISE-2 | 3 | 3 | 366 | 356 | −2.0 [−2.9; −1.2] |
| Eptinezumab, 300 mg/quarter | -/- | 2b | 3 | 116 | 114 | −2.7 [−4.4; −0.9] |
| Dodick et al., 2019 (e38) | ||||||
| Lipton et al., 2020 (e39) | PROMISE-2 | 3 | 3 | 366 | 350 | −2.6 [−3.4; −1.7] |
| Erenumab, 70 mg/month | -/- | 2 | 3 | 281 | 188 | −2.5 [−3.5; −1.4] |
| Tepper et al., 2017 (e40) | ||||||
| Takeshima et al., 2021 (e25) | -/- | 3 | 6 | 50 | 52 | −1.6 [−3.4; 0.2] |
| Yu et al., 2022 (e41) | DRAGON | 3 | 3 | 274 | 270 | −1.6 [−2.8; −0.3] |
| Erenumab, 140 mg/month | -/- | 2 | 3 | 281 | 187 | −2.5 [−3.5; −1.4] |
| Tepper et al., 2017 (e40) | ||||||
| Fremanezumab, 225 mg/month | -/- | 2b | 3 | 89 | 87 | −1.7 [−3.7; 0.2] |
| Bigal et al., 2015 (e42) | ||||||
| Silberstein et al., 2017 (e43)*1 | HALO CM | 3 | 3 | 371 | 375 | −1.8 [−2.6; −1.1] |
| Sakai et al., 2021 (e29) | -/- | 2/3 | 3 | 190 | 187 | −2.1 [−3.1; −1.1] |
| Ferrari et al., 2019 (e30)*2 | FOCUS | 3b | 3 | 111 | 173 | −3.8 [−4.8; −2.8] |
| Fremanezumab, 675 mg/quarter | HALO CM | 3 | 3 | 371 | 375 | −1.7 [−2.5; −1.0] |
| Silberstein et al., 2017 (e43)*1 | ||||||
| Sakai et al., 2021 (e29) | -/- | 2/3 | 3 | 190 | 189 | −1.3 [−2.3; −0.3] |
| Ferrari et al., 2019 (e30)*2 | FOCUS | 3b | 3 | 167 | 169 | −3.2 [−4.2; −2.2] |
| Galcanezumab, 120 mg/month | REGAIN | 3 | 3 | 538 | 273 | −2.1 [−2.9; −1.3] |
| Detke et al., 2018 (e44) | ||||||
| Mulleners et al., 2020 (e35) | CONQUER | 3b | 3 | 98 | 95 | −3.7 [−5.2; −2.2] |
| Galcanezumab, 240 mg/month | REGAIN | 3 | 3 | 538 | 274 | −1.9 [−2.7; −1.1] |
| Detke et al., 2018 (e44) |
In patients receiving preventive treatment with fremanezumab 225 mg/month and galcanezumab 120 mg/month, increased doses of 675 mg and 240 mg, respectively, are administered in the first month. The information from the trial by Bigal et al., 2015, is based on the analysis of moderate to severe headache days. Please refer to the referenced original publications for the statistical models underlying the various values.
Missing information was completed using values from the Clinical Trials Registry https://clinicaltrials.gov/ (data as of 11 July 2025).
The placebo group sizes were supplemented based on the following publication: MaassenVanDenBrink et al., 2021 (e37).
CI, confidence interval; MD, mean difference (migraine days/month), active versus placebo; N, sample size; T, study period